RegulatorContamination and Safety2024

Why peptide impurities matter: FDA on aggregates and immunogenicity

An FDA advisory committee presentation explained how peptide impurities, including aggregates, can raise immunogenicity risk.

Why peptide impurities matter: FDA on aggregates and immunogenicity
Key findings
  • FDA PCAC presentation October 29, 2024, by Russell Wesdyk (CDER Office of Pharmaceutical Quality)
  • Peptide impurities including aggregates can raise immunogenicity risk
  • Immunogenicity can include life-threatening reactions such as anaphylaxis
  • Controlling impurities requires sophisticated manufacturing and testing

On October 29, 2024, the FDA Pharmacy Compounding Advisory Committee heard a presentation from Russell Wesdyk of the CDER Office of Pharmaceutical Quality. The subject was why impurities in peptide products matter more than they do for many conventional small molecules.

The core point is that impurities in peptides — including aggregates, which are clumps of the peptide molecules bound together — can raise the risk of an unwanted immune response. That immunogenicity is not a minor concern; it can include life-threatening reactions such as anaphylaxis. The presentation's practical conclusion was that controlling these impurities requires sophisticated manufacturing and sophisticated testing.

The reason peptides are different is structural. A peptide is a chain of amino acids, and the chain can be made incorrectly — missing a residue (a deletion sequence), cut short (a truncated sequence), oxidized, or stuck to other chains (an aggregate). Each of these is a different impurity, and each can behave differently in the body. A result that says "purity 99%" without saying what the 1% is, and without an impurity profile, hides exactly the things that drive immunogenicity.

This is the regulatory case for putting an impurity profile on a certificate of analysis. It is also the case for identity work: confirming the molecule's mass confirms that the main component is the intended chain, and chromatography shows what else is in the vial. Together they are the characterization the FDA describes as hard.

FDA PCAC, presentation by Russell Wesdyk (CDER Office of Pharmaceutical Quality), October 29, 2024.

Educational information only. Not medical advice. USA Prime Labs tests research materials for research use only; nothing here is intended for human or veterinary use. Talk to a licensed health care provider about any medical decision.
Related articles
USA Prime Labs
USAPRIME LABS
We test the research before you do

We test the research before you do. Identity, purity, content, endotoxin, metals, sterility — verified on one certificate you can check by QR.

All testing is performed on research materials for research use only. Not for human consumption. Results describe the sample as received and do not constitute medical, clinical, or safety advice.

© 2026 USA Prime Labs. Research use only — not for human consumption.Part of the USA Prime family.